Market Currents
GlaxoSmithKline (GSK) and Theravance (THRX) complete Phase III studies for Relovair to treat...
-
Monday, January 9, 2012, 3:10 AM ETGlaxoSmithKline (GSK) and Theravance (THRX) complete Phase III studies for Relovair to treat patients with chronic obstructive pulmonary disease, and complete all but one study for the use of Relovair for asthma. GSK plans to submit regulatory applications to U.S. and EU regulators in mid-2012. (PR)
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
